Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04905693




Registration number
NCT04905693
Ethics application status
Date submitted
20/05/2021
Date registered
28/05/2021
Date last updated
7/11/2024

Titles & IDs
Public title
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Scientific title
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Secondary ID [1] 0 0
RIN-PF-302
Universal Trial Number (UTN)
Trial acronym
TETON-OLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Interstitial Lung Disease 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Inhaled Treprostinil
Treatment: Devices - Treprostinil Ultrasonic Nebulizer

Experimental: Inhaled Treprostinil - Treprostinil inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated to a target of 15 breaths QID or until the subject reaches their maximum clinically tolerated dose.


Treatment: Drugs: Inhaled Treprostinil
Inhaled Treprostinil (6 mcg/breath) administered QID

Treatment: Devices: Treprostinil Ultrasonic Nebulizer
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Long-term safety and tolerability of inhaled treprostinil in subjects with IPF
Timepoint [1] 0 0
Baseline to 6 years

Eligibility
Key inclusion criteria
1. Subject gives voluntary informed consent to participate in the study.
2. The subject participated in Study RIN-PF-301 or Study RIN-PF-303 and remained on study drug and completed all scheduled study visits or was enrolled in Study RIN-PF-301 or Study RIN-PF-303 at the time that the study or study subject was discontinued by the Sponsor.
3. Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at OLE Entry Visit and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.
4. Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
5. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subject is pregnant or lactating.
2. In the opinion of the Investigator, enrollment in Study RIN-PF-302 would represent a risk to the subject's overall health.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2026
Actual
Sample size
Target
792
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Macquarie University - Macquarie Park
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Lung Research Qld - Chermside
Recruitment hospital [5] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [6] 0 0
Mater Misericordiae Ltd - South Brisbane
Recruitment hospital [7] 0 0
Alfred Health - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4032 - Chermside
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Nebraska
Country [19] 0 0
United States of America
State/province [19] 0 0
New Mexico
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Oregon
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
South Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Utah
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Wisconsin
Country [32] 0 0
Argentina
State/province [32] 0 0
Buenos Aires
Country [33] 0 0
Argentina
State/province [33] 0 0
Provincia De Córdoba
Country [34] 0 0
Argentina
State/province [34] 0 0
Provincia De Mendoza
Country [35] 0 0
Argentina
State/province [35] 0 0
Ciudad Autónoma de Buenos Aires
Country [36] 0 0
Belgium
State/province [36] 0 0
Antwerpen
Country [37] 0 0
Belgium
State/province [37] 0 0
Brussels
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Liège
Country [40] 0 0
Chile
State/province [40] 0 0
Maule
Country [41] 0 0
Chile
State/province [41] 0 0
Metropolitana
Country [42] 0 0
Chile
State/province [42] 0 0
Región Metropolitana
Country [43] 0 0
Chile
State/province [43] 0 0
Valparaiso
Country [44] 0 0
Denmark
State/province [44] 0 0
Aarhus N
Country [45] 0 0
Denmark
State/province [45] 0 0
Hellerup
Country [46] 0 0
Denmark
State/province [46] 0 0
Odense C
Country [47] 0 0
France
State/province [47] 0 0
Bouches-du-Rhône
Country [48] 0 0
France
State/province [48] 0 0
Haute-Garonne
Country [49] 0 0
France
State/province [49] 0 0
Indre-et-Loire
Country [50] 0 0
France
State/province [50] 0 0
Amiens
Country [51] 0 0
France
State/province [51] 0 0
Bobigny
Country [52] 0 0
France
State/province [52] 0 0
Bron
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
France
State/province [54] 0 0
Reims
Country [55] 0 0
France
State/province [55] 0 0
Rennes
Country [56] 0 0
Israel
State/province [56] 0 0
HaDarom
Country [57] 0 0
Israel
State/province [57] 0 0
Haifa
Country [58] 0 0
Israel
State/province [58] 0 0
HaMerkaz
Country [59] 0 0
Israel
State/province [59] 0 0
Tel-Aviv
Country [60] 0 0
Israel
State/province [60] 0 0
Yerushalayim
Country [61] 0 0
Israel
State/province [61] 0 0
Kfar Saba
Country [62] 0 0
Israel
State/province [62] 0 0
Petah Tiqva
Country [63] 0 0
Israel
State/province [63] 0 0
Tel Aviv
Country [64] 0 0
Italy
State/province [64] 0 0
Emilia-Romagna
Country [65] 0 0
Italy
State/province [65] 0 0
Lazio
Country [66] 0 0
Italy
State/province [66] 0 0
Sicilia
Country [67] 0 0
Italy
State/province [67] 0 0
Toscana
Country [68] 0 0
Italy
State/province [68] 0 0
Ancona
Country [69] 0 0
Italy
State/province [69] 0 0
Forlì
Country [70] 0 0
Italy
State/province [70] 0 0
Roma
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Gyeonggido
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Incheon Gwang'yeogsi
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Seoul Teugbyeolsi
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Seoul
Country [75] 0 0
Mexico
State/province [75] 0 0
Nuevo León
Country [76] 0 0
Mexico
State/province [76] 0 0
Ciudad de Mexico
Country [77] 0 0
Netherlands
State/province [77] 0 0
Zuid-Holland
Country [78] 0 0
New Zealand
State/province [78] 0 0
Waikato
Country [79] 0 0
New Zealand
State/province [79] 0 0
Christchurch
Country [80] 0 0
Spain
State/province [80] 0 0
Baleares
Country [81] 0 0
Spain
State/province [81] 0 0
Barcelona
Country [82] 0 0
Spain
State/province [82] 0 0
Málaga
Country [83] 0 0
Spain
State/province [83] 0 0
Granada
Country [84] 0 0
Spain
State/province [84] 0 0
Madrid
Country [85] 0 0
Spain
State/province [85] 0 0
Murcia
Country [86] 0 0
Spain
State/province [86] 0 0
Santander
Country [87] 0 0
Taiwan
State/province [87] 0 0
Kaohsiung
Country [88] 0 0
Taiwan
State/province [88] 0 0
New Taipei City
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
United Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
Trial website
https://clinicaltrials.gov/study/NCT04905693
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04905693